Er vindt onderhoud plaats aan de Radboud Repository. Het is mogelijk dat uw zoekactie incomplete resultaten oplevert. Indien u publicaties wilt uploaden kunt u dit doen via de Upload Full Text button. Radboud Repository is undergoing maintenance. Please note that your search may produce incomplete results. If you would like to upload publications, you can do so by means of the Upload Full Text button.
The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida.
until further notice
SourceJournal of Molecular Medicine-Jmm, 84, 12, (2006), pp. 1047-54
Article / Letter to editor
Display more detailsDisplay less details
Paediatrics - OUD tm 2017
Epidemiology, Biostatistics & HTA
Journal of Molecular Medicine-Jmm
SubjectEBP 1: Determinants in Health and Disease; IGMD 3: Genomic disorders and inherited multi-system disorders; IGMD 5: Health aging / healthy living; IGMD 6: Hormonal regulation; NCEBP 14: Cardiovascular diseases; NCEBP 1: Molecular epidemiology; NCMLS 4: Energy and redox metabolism; ONCOL 3: Translational research; UMCN 1.5: Interventional oncology; UMCN 2.2: Vascular medicine and diabetes; UMCN 5.2: Endocrinology and reproduction
The methionine synthase reductase (MTRR) enzyme restores methionine synthase (MTR) enzyme activity and therefore plays an essential role in homocysteine remethylation. In some studies, the 66A>G polymorphism in the MTRR gene was associated with increased neural tube defect (NTD) risk. Using a case-control design, we studied the association between the MTRR 66A>G polymorphism and spina bifida risk in 121 mothers, 109 spina bifida patients, 292 control women, and 234 pediatric controls. Possible interactions between the MTRR 66A>G variant and the MTR 2756A>G polymorphism, the MTHFR 677C>T variant, plasma vitamin B12, and plasma methylmalonic acid (MMA) levels were examined in the 121 mothers and 292 control women. Meta-analyses were conducted to set the results of the case-control study in the context of eligible literature on the relation between the MTRR 66A>G variant and NTD risk. Finally, a transmission disequilibrium test was performed for 82 complete mother-father-child triads to test for preferential transmission of the MTRR risk allele. In our case-control study, the MTRR 66A>G polymorphism had no influence on spina bifida risk in children [odds ratio (OR) 0.6, 95% confidence interval (CI) 0.4-1.1]. The MTRR 66GG genotype increased maternal spina bifida risk by 2.1-fold (OR 2.1, 95% CI 1.3-3.3). This risk became more pronounced in combination with the MTHFR 677TT genotype (OR 4.0, 95% CI 1.3-12.5). Moreover, we demonstrate a possible interaction between the MTRR 66GG genotype and high plasma MMA levels (OR 5.5, 95% CI 2.2-13.5). The meta-analyses demonstrated that the maternal MTRR 66GG genotype was associated with an overall 55% (95% CI 1.04-2.30) increase in NTD risk and that the MTRR 66GG genotype did not increase NTD risk in children (OR 0.96, 95% CI 0.46-2.01). These data show that the MTRR 66GG genotype is a maternal risk factor for spina bifida especially when intracellular vitamin B12 status is low.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.